Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of ...

Akero Therapeutics shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

Proceeds from the offering will support ongoing clinical trials, particularly for their lead candidate, pegozafermin, as well as manufacturing costs and general corporate expenses. The offering is ...

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

The company is focused on advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis and severe ...